Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948320538> ?p ?o ?g. }
- W2948320538 abstract "Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naïve hepatocellular carcinoma (HCC) demonstrated an overall survival (OS) benefit. This randomized, open-label Phase IIb trial investigated whether Pexa-Vec plus Best Supportive Care (BSC) improved OS over BSC alone in HCC patients who failed sorafenib therapy (TRAVERSE).129 patients were randomly assigned 2:1 to Pexa-Vec plus BSC vs. BSC alone. Pexa-Vec was given as a single intravenous (IV) infusion followed by up to 5 IT injections. The primary endpoint was OS. Secondary endpoints included overall response rate (RR), time to progression (TTP) and safety.A high drop-out rate in the control arm (63%) confounded assessment of response-based endpoints. Median OS (ITT) for Pexa-Vec plus BSC vs. BSC alone was 4.2 and 4.4 months, respectively (HR, 1.19, 95% CI: 0.78–1.80; p = .428). There was no difference between the two treatment arms in RR or TTP. Pexa-Vec was generally well-tolerated. The most frequent Grade 3 included pyrexia (8%) and hypotension (8%). Induction of immune responses to vaccinia antigens and HCC associated antigens were observed.Despite a tolerable safety profile and induction of T cell responses, Pexa-Vec did not improve OS as second-line therapy after sorafenib failure. The true potential of oncolytic viruses may lie in the treatment of patients with earlier disease stages which should be addressed in future studies.ClinicalTrials.gov: NCT01387555" @default.
- W2948320538 created "2019-06-14" @default.
- W2948320538 creator A5001637416 @default.
- W2948320538 creator A5002048735 @default.
- W2948320538 creator A5003920642 @default.
- W2948320538 creator A5005443438 @default.
- W2948320538 creator A5006848714 @default.
- W2948320538 creator A5007159753 @default.
- W2948320538 creator A5008020207 @default.
- W2948320538 creator A5012458272 @default.
- W2948320538 creator A5017292777 @default.
- W2948320538 creator A5018321708 @default.
- W2948320538 creator A5018939712 @default.
- W2948320538 creator A5019082757 @default.
- W2948320538 creator A5020956671 @default.
- W2948320538 creator A5020985866 @default.
- W2948320538 creator A5022933940 @default.
- W2948320538 creator A5026090288 @default.
- W2948320538 creator A5027920046 @default.
- W2948320538 creator A5029856265 @default.
- W2948320538 creator A5032835455 @default.
- W2948320538 creator A5033267651 @default.
- W2948320538 creator A5035954494 @default.
- W2948320538 creator A5038131926 @default.
- W2948320538 creator A5042377707 @default.
- W2948320538 creator A5044195657 @default.
- W2948320538 creator A5046190075 @default.
- W2948320538 creator A5048632906 @default.
- W2948320538 creator A5050993604 @default.
- W2948320538 creator A5053299889 @default.
- W2948320538 creator A5054250864 @default.
- W2948320538 creator A5054558069 @default.
- W2948320538 creator A5057343843 @default.
- W2948320538 creator A5062715691 @default.
- W2948320538 creator A5063860482 @default.
- W2948320538 creator A5071770850 @default.
- W2948320538 creator A5072104273 @default.
- W2948320538 creator A5082631947 @default.
- W2948320538 creator A5090004161 @default.
- W2948320538 date "2019-06-03" @default.
- W2948320538 modified "2023-10-09" @default.
- W2948320538 title "Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)" @default.
- W2948320538 cites W1507996114 @default.
- W2948320538 cites W170602106 @default.
- W2948320538 cites W1828082159 @default.
- W2948320538 cites W1971273486 @default.
- W2948320538 cites W1971837077 @default.
- W2948320538 cites W1994193851 @default.
- W2948320538 cites W1997533142 @default.
- W2948320538 cites W2000307707 @default.
- W2948320538 cites W2011513757 @default.
- W2948320538 cites W2020849247 @default.
- W2948320538 cites W2051684210 @default.
- W2948320538 cites W2052730188 @default.
- W2948320538 cites W2075631864 @default.
- W2948320538 cites W2079586464 @default.
- W2948320538 cites W2079647238 @default.
- W2948320538 cites W2079990421 @default.
- W2948320538 cites W2080857945 @default.
- W2948320538 cites W2081188511 @default.
- W2948320538 cites W2093059993 @default.
- W2948320538 cites W2097849707 @default.
- W2948320538 cites W2100158834 @default.
- W2948320538 cites W2108883303 @default.
- W2948320538 cites W2109274792 @default.
- W2948320538 cites W2128965737 @default.
- W2948320538 cites W2135003182 @default.
- W2948320538 cites W2137813001 @default.
- W2948320538 cites W2138572955 @default.
- W2948320538 cites W2140167398 @default.
- W2948320538 cites W2140765540 @default.
- W2948320538 cites W2153935627 @default.
- W2948320538 cites W2166122359 @default.
- W2948320538 cites W2179055275 @default.
- W2948320538 cites W2329082954 @default.
- W2948320538 cites W2546700240 @default.
- W2948320538 cites W2560499218 @default.
- W2948320538 cites W2606367731 @default.
- W2948320538 cites W2626033245 @default.
- W2948320538 cites W2787358630 @default.
- W2948320538 cites W2792376809 @default.
- W2948320538 cites W2795055433 @default.
- W2948320538 cites W2805592007 @default.
- W2948320538 cites W2809889937 @default.
- W2948320538 cites W2908573150 @default.
- W2948320538 cites W2997727194 @default.
- W2948320538 cites W4211238487 @default.
- W2948320538 doi "https://doi.org/10.1080/2162402x.2019.1615817" @default.
- W2948320538 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6682346" @default.
- W2948320538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31413923" @default.
- W2948320538 hasPublicationYear "2019" @default.
- W2948320538 type Work @default.
- W2948320538 sameAs 2948320538 @default.
- W2948320538 citedByCount "78" @default.
- W2948320538 countsByYear W29483205382019 @default.
- W2948320538 countsByYear W29483205382020 @default.
- W2948320538 countsByYear W29483205382021 @default.
- W2948320538 countsByYear W29483205382022 @default.
- W2948320538 countsByYear W29483205382023 @default.
- W2948320538 crossrefType "journal-article" @default.